Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RapMed-2302
- Development stage
- Unknown
- Lead developer
- RAPHAS
- Modality
- Small Molecules
- Administration
- Topical, Percutaneous
01
Overview
RapMed-2302 is a dissolving microneedle patch formulation of clindamycin phosphate, currently under development by RAPHAS for the treatment of acne vulgaris. The product utilizes RAPHAS's proprietary Droplet Extension Conduction (DEN) technology to create microneedles that penetrate the stratum corneum and dissolve to deliver the active ingredient directly into the skin. Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively targeting *Cutibacterium acnes*. This delivery method aims to provide higher local concentrations of the drug with potentially fewer systemic or surface-level side effects compared to traditional topical treatments. RapMed-2302 is currently in Phase 1 clinical trials in South Korea.
- Other names
- clindamycin phosphate microneedle patch
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on RapMed-2302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RapMed-2302.